The elimination of P-glycoprotein over-expressing cancer cells by antimicrobial cationic peptide NK-2: The unique way of multi-drug resistance modulation

Experimental Cell Research

Volumn 319, Issue 7, 2013, Pages 1013-1027

  Banković, Jasna ^a   Andrä, Jörg ^b   Todorović, Nataša ^a   Podolski Renić, Ana ^a   Milošević, Zorica ^a   Miljković, Dorde ^a   Krause, Jannike ^b,c   Ruždijić, Sabera ^a   Tanić, Nikola ^a   Pešić, Milica ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b RESEARCH CENTER BORSTEL   (Germany)

^c HAMBURG UNIVERSITY OF APPLIED SCIENCES   (Germany)

Author keywords

Antimicrobial peptide; Melittin; Multi drug resistant cancer cells; NK lysin; P glycoprotein

Indexed keywords

ANTIMICROBIAL CATIONIC PEPTIDE NK 2; ANTIMICROBIAL CATIONIC PEPTIDE NK11; DOXORUBICIN; MELITTIN; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; PHOSPHATIDYLSERINE; POLYPEPTIDE ANTIBIOTIC AGENT; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL MEMBRANE; CELL STRUCTURE; CELL SURVIVAL; COLORECTAL CARCINOMA; CONTROLLED STUDY; DRUG POTENTIATION; HUMAN; HUMAN CELL; IC 50; LUNG NON SMALL CELL CANCER; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN TRANSPORT;

EID: 84874995830     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2012.12.017     Document Type: Article

References (57)

1. Smith L.L., Brow K., Carthew P., Lim C.K., Martin E.A., Styles J., White I.N. Chemoprevention of breast cancer by tamoxifen: risks and opportunities. Crit. Rev. Toxicol. 2000, 30:571-594.
2. Dunn G.P., Bruce A.T., Ikeda H., Old L.J., Schreiber R.D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 2002, 3:991-998.
3. Garnier-Suillerot A., Marbeuf-Gueye C., Salerno M., Loetchutinat C., Fokt I., Krawczyk M., Kowalczyk T., Priebe W. Analysis of drug transport kinetics in multidrug-resistant cells: implications for drug action. Curr. Med. Chem. 2001, 8:51-64.
4. Leuschner C., Hansel W. Membrane disrupting lytic peptides for cancer treatments. Curr. Pharm. Des. 2004, 10:2299-2310.
5. Bechinger B., Lohner K. Detergent-like actions of linear amphipathic cationic antimicrobial peptides. Biochim. Biophys. Acta 2006, 1758:1529-1539.
6. Chen Y.Q., Min C., Sang M., Han Y.Y., Ma X., Xue X.Q., Zhang S.Q. A cationic amphiphilic peptide ABP-CM4 exhibits selective cytotoxicity against leukemia cells. Peptides 2010, 31:1504-1510.
7. Cruciani R.A., Barker J.L., Zasloff M., Chen H.C., Colamonici O. Antibiotic magainins exert cytolytic activity against transformed cell lines through channel formation. Proc. Natl. Acad. Sci. USA 1991, 88:3792-3796.
8. Hui L., Leung K., Chen H.M. The combined effects of antibacterial peptide cecropin A and anti-cancer agents on leukemia cells. Anticancer Res. 2002, 22:2811-2816.
9. Hammer M., Brauser A., Olak C., Brezesinski G., Goldmann T., Gutsmann T., Andrä J. Lipopolysaccharide interaction is decisive for the activity of the antimicrobial peptide NK-2 against Escherichia coli and Proteus mirabilis. Biochem. J. 2010, 427:477-488.
10. Zachowski A. Phospholipids in animal eukaryotic membranes: transverse asymmetry and movement. Biochem. J. 1993, 294:1-14.
11. Lohner K., Prenner E.J. Differential scanning calorimetry and X-ray diffraction studies of the specificity of the interaction of antimicrobial peptides with membrane-mimetic systems. Biochim. Biophys. Acta 1999, 1462:141-156.
12. Zwaal R., Schroit A. Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood 1997, 89:1121-1132.
13. Manno S., Takakuwa Y., Mohandas N. Identification of a functional role for lipid asymmetry in biological membranes: phosphatidylserine-skeletal protein interactions modulate membrane stability. Proc. Natl. Acad. Sci. USA 2002, 99:1943-1948.
14. Schroit A.J., Madsen J.W., Tanaka Y. In vivo recognition and clearance of red blood cells containing phosphatidylserine in their plasma membranes. J. Biol. Chem. 1985, 260:5131-5138.
15. Fadok V.A., Voelker D.R., Campbell P.A., Cohen J.J., Bratton D.L., Henson P.M. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J. Immunol. 1992, 148:2207-2216.
16. Utsugi T., Schroit A.J., Connor J., Bucana C.D., Fidler I.J. Elevated expression of phosphatidylserine in the outer membrane leaflet of human tumor cells and recognition by activated human blood monocytes. Cancer Res. 1991, 51:3062-3066.
17. Ran S., Downes A., Thorpe P.E. Increased exposure of anionic phospholipids on the surface of tumor blood vessels. Cancer Res. 2002, 62:6132-6140.
18. Schröder-Borm H., Bakalova R., Andrä J. The NK-lysin derived peptide NK-2 preferentially kills cancer cells with increased surface levels of negatively charged phosphatidylserine. FEBS Lett. 2005, 579:6128-6134.
19. S. Riedl, B. Rinner, M. Asslaber, H. Schaider, S. Walzer, A. Novak, K. Lohner, D. Zweyticka, In search of a novel target-phosphatidylserine exposed by non-apoptotic tumor cells and metastases of malignancies with poor treatment efficacy, Biochim. Biophys. Acta 1808 (2011) 2638-2645.
20. Nobili S., Landini I., Mazzei T., Mini E. Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression. Med. Res. Rev. 2012, 32:1220-1262.
21. Pohl A., Lage H., Müller P., Pomorski T., Herrmann A. Transport of phosphatidylserine via MDR1 (multidrug resistance 1) P-glycoprotein in a human gastric carcinoma cell line. Biochem. J. 2002, 365:259-268.
22. Schröder-Borm H., Willumeit R., Brandenburg K., Andrä J. Molecular basis for membrane selectivity of NK-2, a potent peptide antibiotic derived from NK-lysin. Biochim. Biophys. Acta 2003, 1612:164-171.
23. Shai Y. Mechanism of the binding, insertion and destabilization of phospholipid bilayer membranes by alpha-helical antimicrobial and cell non-selective membrane-lytic peptides. Biochim. Biophys. Acta 1999, 1462:55-70.
24. Oren Z., Shai Y. Mode of action of linear amphipathic alpha-helical antimicrobial peptides. Biopolymers 1998, 47:451-463.
25. Drechsler S., Andrä J. Online monitoring of metabolism and morphology of peptide-treated neuroblastoma cancer cells and keratinocytes. J. Bioenergy Biomembr. 2011, 43:275-285.
26. Pesic M., Markovic J., Jankovic D., Kanazir S., Markovic I., Rakic L., Ruzdijic S. Induced resistance in the human non small cell lung carcinoma (NCI-H460) cell line in vitro by anticancer drugs. J. Chemother. 2006, 18:66-73.
27. Podolski-Renić A., Andelković T., Banković J., Tanić N., Ruždijić S., Pešić M. The role of paclitaxel in the development and treatment of multidrug resistant cancer cell lines. Biomed. Pharmacother. 2011, 65:345-353.
28. Johnstone S.A., Gelmon K., Mayer L.D., Hancock R.E., Bally M.B. In vitro characterization of the anticancer activity of membraneactive cationic peptides. I. Peptide-mediated cytotoxicity and peptide-enhanced cytotoxic activity of doxorubicin against wildtype and p-glycoprotein over-expressing tumor cell lines, Anticanc. Drug Des. 2000, 15:151-160.
29. Kim S., Kim S.S., Bang Y.J., Kim S.J., Lee B.J. In vitro activities of native and designed peptide antibiotics against drug sensitive and resistant tumor cell lines. Peptides 2003, 24:945-953.
30. Wang K.R., Yan J.X., Zhang B.Z., Song J.J., Jia P.F., Wang R. Novel mode of action of polybia-MPI, a novel antimicrobial peptide, in multi-drug resistant leukemic cells. Cancer Lett. 2009, 278:65-72.
31. Chuang C.M., Monie A., Wu A., Mao C.P., Hung C.F. Treatment with LL-37 peptide enhances the antitumor effects induced by CpG oligodeoxynucleotides against ovarian cancer. Hum. Gene Ther. 2009, 20:303-313.
32. Ohsaki Y., Gazdar A.F., Chen H.C., Johnson B.E. Antitumor activity of magainin analogues against human lung cancer cell lines. Cancer Res. 1992, 52:3534-3538.
33. Papo N., Braunstein A., Eshhar Z., Shai Y. Suppression of human prostate tumor growth in mice by a cytolytic d-, l-amino acid peptide: membrane lysis, increased necrosis and inhibition of prostate-specific antigen secretion. Cancer Res. 2004, 64:5779-5786.
34. Gross S., Andrä J. Anticancer peptide NK-2 targets cell surface sulphated glycans rather than sialic acids. Biol. Chem. 2012, 393:817-827.
35. Hamill O.P., Marty A., Neher E., Sackmann B., Sigworth F.J. Improved patch-clamp technique for high resolution current recording from cells and cell-free membrane patches. Pflugers Arch. 1981, 391:85-100.
36. Bösch S., Siavoshian S., Jacquot C., Tomasoni C., Dabouis G., Elanbaloussi Y., Leneel T., More M.T., Roussakis C. Correlation between multidrug resistance and the degree of differentiation of non-small-cell bronchopulmonary carcinoma (NSCLC) in vitro and in vivo. Anticancer Res. 1997, 17:4595-4598.
37. Wong H., Anderson W.D., Cheng T., Riabowol K.T. Monitoring mRNA expression by polymerase chain reaction: the primer-dropping method. Anal. Biochem. 1994, 223:251-258.
38. Riordan J.R., Deuchars K., Kartner N., Alon N., Trent J., Ling V. Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines. Nature 1985, 316:817-819.
39. Goldstein L.J. MDR1 gene expression in solid tumours. Eur. J. Cancer 1996, 32A:1039-1050.
40. Ernst R., Kueppers P., Stindt J., Kuchler K., Schmitt L. Multidrug efflux pumps: Substrate selection in ATP-binding cassette multidrug efflux pumps-first come, first served?. FEBS J. 2010, 277:540-549.
41. Szakács G., Paterson J.K., Ludwig J.A., Booth-Genthe C., Gottesman M.M. Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 2006, 5:219-234.
42. Shukla S., Wu C.P., Ambudkar S.V. Development of inhibitors of ATP-binding cassette drug transporters: Present status and challenges. Expert Opin. Drug Metab. Toxicol. 2008, 4:205-223.
43. Blagosklonny M.V. Targeting cancer cells by exploiting their resistance. Trends Mol. Med. 2003, 9:307-312.
44. i homeostasis in multidrug-resistant (MDR) cells: further characterization of a series of MDR cell lines expressing different levels of P-glycoprotein. Biochemistry 1993, 32:11042-11056.
45. De Milito A., Fais S. Tumor acidity, chemoresistance and proton pump inhibitors. Future Oncol. 2005, 1:779-786.
46. Thews O., Gassner B., Kelleher D.K., Schwerdt G., Gekle M. Impact of extracellular acidity on the activity of P-glycoprotein and the cytotoxicity of chemotherapeutic drugs. Neoplasia 2006, 8:143-152.
47. Harguindey S., Arranz J.L., Wahl M.L., Orive G., Reshkin S.J. Proton transport inhibitors as potentially selective anticancer drugs. Anticancer Res. 2009, 29:2127-2136.
48. Zwaal R., Schroit A. Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood 1997, 89:1121-1132.
49. Papo N., Shai Y. Host defense peptides as new weapons in cancer treatment. Cell Mol. Life Sci. 2005, 62:784-790.
50. Sharom F.J., DiDiodato G., Yu X., Ashbourne K.J.D. Interaction of the P-glycoprotein multidrug transporter with peptides and ionophores. J. Biol. Chem. 1995, 270:10334-10341.
51. Andrä J., Goldmann T., Ernst C.M., Peschel A., Gutsmann T. Multiple peptide resistance factor (MprF)-mediated Resistance of Staphylococcus aureus against antimicrobial peptides coincides with a modulated peptide interaction with artificial membranes comprising lysyl-phosphatidylglycerol. J. Biol. Chem. 2011, 286:18692-186700.
52. Gelhaus C., Jacobs T., Andrä J., Leippe M. The antimicrobial peptide NK-2, the core region of mammalian NK-lysin, kills intraerythrocytic Plasmodium falciparum. Antimicrob Agents Chemother. 2008, 52:1713-1720.
53. Garrigos M., Belehradek J., Mir L.M., Orlowski S. Absence of cooperativity for MgATP and verapamil effects on the ATPase activity of P-glycoprotein containing membrane vesicles. Biochem. Biophys. Res. Commun. 1993, 196:1034-1041.
54. Fox E., Bates S.E. Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor. Expert Rev. Anticancer Ther. 2007, 7:447-459.
55. R. Willumeit, M. Kumpugdee, S.S. Funari, K. Lohner, B.P. Navas, K. Brandenburg, S. Linser, J. Andrä, Structural rearrangement of model membranes by the peptide antibiotic NK-2, Biochim. Biophys. Acta 1669 (2005) 125-134.
56. Orlowski S., Martin S., Escargueil A. P-glycoprotein and 'lipid rafts': some ambiguous mutual relationships (floating on them, building them or meeting them by chance?. Cell Mol. Life Sci. 2006, 63:1038-1059.
57. Sharom F.J. ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics 2008, 9:105-127.